Daratumumab in the News Again: Showing Benefit in Frontline and at Relapse

Submitted by blackswan on Sat, 09/02/2017 - 00:10

On August 24th, Genmab announced that the ALCYONE trial, which compared the combination of daratumumab (Darzalex®) with VMP (Velcade®/melphalan/prednisone) to VMP alone, hit the primary endpoint for treatment of myeloma as a frontline therapy. The progression-free survival (PFS) for the VMP alone was 18.1 months versus “not reached” with the addition of daratumumab. Showing the added value of daratumumab is very important in Europe, where VMP is a standard frontline regimen.

With the Solar Eclipse, Millions Understand That Science is Not Fake News

Submitted by blackswan on Fri, 08/25/2017 - 20:57

At 10:21 a.m. Los Angeles time on Monday, August 21st, the moon covered 62% of the sun. In Oregon and across the US, there were 2.3 minutes of total darkness. Scientists had been informing everyone about this upcoming event for many years, and it occurred exactly on schedule: a natural event.

Positive Butterfly News, Immune Tweaking with CRISPR, and Looking to the Future in China

Submitted by blackswan on Fri, 08/11/2017 - 01:37

As I reported in a previous blog, not only does the herbicide Roundup cause lymphomas and myeloma, its widespread use on GMO (genetically modified organism) crops has decimated milkweed, an herbaceous perennial and the essential food for monarch butterflies. Since 1990, about 970 million monarchs have vanished.

Gene Editing, Regulating DNA Sequencing Tests, and How Your Body Gets Its Energy

Submitted by blackswan on Thu, 08/03/2017 - 12:30

Scientific breakthroughs in the news this week promise many practical implications for myeloma patients.

Saturated fat reconsidered, traces of herbicide in ice cream, and a curcumin success story

Submitted by blackswan on Fri, 07/28/2017 - 01:27

News about food is often a mix of conflicting advice and dubious claims. Three thought-provoking articles published this week caught my eye and offer plenty of food for thought.

Pages

more